银屑病及银屑病关节炎系统治疗患者疫苗接种建议:NPF德尔菲共识
美国国家银屑病基金会医学委员会等基于改良德尔菲法制定22条共识,评估接受系统治疗的银屑病/银屑病关节炎成人接种非活疫苗或活疫苗时是否需暂停治疗,并给出相应推荐。
要点
- 非活疫苗接种通常无需中断多数口服及生物制剂治疗。
- 非活疫苗接种前可考虑中断甲氨蝶呤。
- 活疫苗接种前后需停用多数口服及生物制剂。
核心结论
- 接受非活疫苗者一般无需中断抗银屑病口服及生物制剂治疗。
- 多数情况下建议在活疫苗接种前后暂时中断口服及生物制剂治疗。
研究设计与样本
- 采用改良德尔菲流程,由美国国家银屑病基金会医学委员会、COVID-19工作组及感染病专家共同制定22条共识声明。
主要发现
- 对非活疫苗,多数口服及生物制剂无需调整,但可考虑中断甲氨蝶呤。
- 对活疫苗,多数口服及生物制剂需在接种前后停用。
- 活疫苗前多数生物制剂需停用2–3个半衰期(阿巴西普除外),接种后推迟下次给药2–4周。
关键数值与推荐
- 非活疫苗:多数口服及生物制剂无需调整;考虑中断甲氨蝶呤。
- 活疫苗:多数口服及生物制剂接种前后停用。
- 活疫苗前多数生物制剂停用2–3个半衰期(阿巴西普除外),接种后推迟下次给药2–4周。
临床怎么用
- 接诊时先区分疫苗类型(非活/活)再决定是否暂停系统治疗。
- 非活疫苗通常维持原方案,仅评估甲氨蝶呤是否需中断。
- 活疫苗需按共识规划停用多数口服/生物制剂及后续给药时间。
局限性
- 缺乏疫苗接种后感染率的研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For psoriatic patients who need to receive nonlive or live vaccines, evidence-based recommendations are needed regarding whether to pause or continue systemic therapies for psoriasis and/or psoriatic arthritis. OBJECTIVE: To evaluate literature regarding vaccine efficacy and safety and to generate consensus-based recommendations for adults receiving systemic therapies for psoriasis and/or psoriatic arthritis receiving nonlive or live vaccines. METHODS: Using a modified Delphi process, 22 consensus statements were developed by the National Psoriasis Foundation Medical Board and COVID-19 Task Force, and infectious disease experts. RESULTS: Key recommendations include continuing most oral and biologic therapies without modification for patients receiving nonlive vaccines; consider interruption of methotrexate for nonlive vaccines. For patients receiving live vaccines, discontinue most oral and biologic medications before and after administration of live vaccine. Specific recommendations include discontinuing most biologic therapies, except for abatacept, for 2-3 half-lives before live vaccine administration and deferring next dose 2-4 weeks after live vaccination. LIMITATIONS: Studies regarding infection rates after vaccination are lacking. CONCLUSION: Interruption of antipsoriatic oral and biologic therapies is generally not necessary for patients receiving nonlive vaccines. Temporary interruption of oral and biologic therapies before and after administration of live vaccines is recommended in most cases.
引用
- Chat VS, Ellebrecht CT, Kingston P, et al. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2024. PMID: 38331098. doi:10.1016/j.jaad.2023.12.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。